BOPI 01 BR / 2025 REPERTOIRE NUMERIQUE 25 Figure 1 ________________________________________ (11) 21775 Consulter le mémoire (51) A61K 35/17 (2023.01); A61P 31/18 (2023.01); C07K 14/725 (2023.01); C07K 14/73 (2023.01); C07K 16/10 (2023.01); C12N 15/113 (2023.01) ; C12N 5/0783 (2023.01) (21) 1202400237 - PCT/CN2022/143440 (22) 29/12/2022 (30) CN n° 202111666522.1 du 31/12/2021 et CN n° 202210350268.2 du 02/04/2022 (54) Chimeric antigen receptor T cells targeting HIV-infected cells. (72) YANG, Ying (CN); ZHU, Weijun (CN); WANG, Hongwei (CN) et FAN, Jundie (CN) (73) BEIJING SOLOBIO GENETECHNOLOGY CO., LTD., Room 401, Building 5, No. 36, Jinghai Er Road, Beijing Economic - Technological Development Area, BEIJING 100176 (CN) (74) ALEMBONG OSWALD AMIN, S/C Von Seidels Cameroon Sarl, Easy Office Building, Centre de l'Artisanat, Carrefour Intendance, B.P. 30188, YAOUNDE (CM). (57) One aspect of the present application relates to a recombinant cell comprising a chimeric antigen receptor and shRNA targeted to inhibit the life cycle of HIV. Another aspect of the present application relates to a chimeric antigen molecule, the extracellular region of which is from or comprising the extracellular region of human CD4 molecule, the transmembrane region of which is from or comprising the transmembrane domain of CD8a, and a recombinant cell comprising the above chimeric antigen molecule. The above recombinant cell can be used to treat HIV infection, and have stronger comprehensive killing efficacy, longer effective time, and less risk of causing cytokine storm in the environment of HIV infection. Figure 2 A ________________________________________ (11) 21776 Consulter le mémoire
RkJQdWJsaXNoZXIy MTM1NDc3MA==